logo
The GameStop stapler that punctured a Nintendo Switch 2 console is now on eBay for $250,000

The GameStop stapler that punctured a Nintendo Switch 2 console is now on eBay for $250,000

An innocuous black stapler became public enemy No. 1 for some New York City-based gamers after it damaged a Nintendo Switch 2 at a local GameStop in June.
Now, GameStop has turned that viral mishap into a marketing opportunity: That same stapler, and some additional items, are now selling on eBay for nearly $250,000 as part of a GameStop-organized charity auction.
As of Saturday, there were almost 300 bids.
"Let's consider this GameStop's version of 'corporate accountability,'" a GameStop spokesperson told Business Insider.
The saga — dubbed "staplegate" — began last month when the highly anticipated Nintendo Switch 2 became available to the public. It had been a long road for fans, who were introduced to the original Nintendo Switch eight years ago and were forced to weather a tariff-related delay on the newest version of the popular gaming console. The Nintendo Switch 2 sells for $499.
While many fans received their Nintendo Switch 2 orders without fuss, some said their consoles arrived damaged with puncture holes on the screen. The culprit was a lone stapler at a Staten Island GameStop used to secure the receipts to the console boxes.
Although GameStop replaced the damaged consoles, the company spokesperson said it wanted to "turn the snafu into something for a good cause."
The winning bidder will receive four items: a stapled Nintendo Switch 2 (now fixed), the console's box with stapler marks, the stapler, and the "carefully extracted" staple.
The winner will also get a very personal item from GameStop CEO Ryan Cohen, who said in an X post on Wednesday that he'd include his underwear in the auction if bids surpassed six figures.
They did. By Thursday, Cohen told his X followers that if the auction reached seven figures, he'd "fly the winner to Miami, take them to McDonald's for lunch and personally deliver my preowned underwear."
The GameStop spokesperson said the decision to auction the items was a no-brainer.
"It pitched itself, honestly. Once the story took off, the stapler basically demanded an agent," they said.
Fortunately, tracking down the stapler wasn't difficult.
"We asked nicely and it was surrendered peacefully to our social media and marketing team," the spokesperson said, adding that the response has "exceeded our expectations."
All proceeds from the auction will go to the Children's Miracle Network Hospitals. GameStop will stop accepting bids on July 16.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's Why Omnicom (OMC) is a Strong Momentum Stock
Here's Why Omnicom (OMC) is a Strong Momentum Stock

Yahoo

time24 minutes ago

  • Yahoo

Here's Why Omnicom (OMC) is a Strong Momentum Stock

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. New York-based Omnicom is one of the largest advertising, marketing, and corporate communications companies in the world. The company's networks, practice areas, and agencies offer a comprehensive suite of services across global, pan-regional, and local levels, spanning the following fundamental disciplines: Media & Advertising, Precision Marketing, Public Relations, Healthcare, Branding & Retail Commerce, Experiential, and Execution & Support. These disciplines are areas of professional expertise or service within the broader field of marketing, communications, and advertising. OMC sits at a Zacks Rank #2 (Buy), holds a Momentum Style Score of A, and has a VGM Score of B. The stock is down 2.6% and up 4.7% over the past one-week and four-week period, respectively, and Omnicom has lost 22% in the last one-year period as well. Additionally, an average of 4,640,654 shares were traded over the last 20 trading sessions. A company's earnings performance is important for momentum investors as well. For fiscal 2025, two analysts revised their earnings estimate higher in the last 60 days for OMC, while the Zacks Consensus Estimate has increased $0.01 to $8.33 per share. OMC also boasts an average earnings surprise of 3.7%. OMC should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicom Group Inc. (OMC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Yahoo

time30 minutes ago

  • Yahoo

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store